Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: buprenorphine alone Clear all
Withdrawn Phase 3 Interventional

Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)

NCT04455802
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Buprenorphine or Placebo, Morphine or Placebo
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine for Prisoners

NCT00574067
View directory record Official record
Conditions
Heroin Addiction
Interventions
Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP, Counseling +CHC
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Jessup, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

NCT05704543
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine Extended-Release Injection
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
San Diego, California • Hollywood, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Early Phase 1 Interventional

Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty

NCT02991404
View directory record Official record
Conditions
Total Knee Arthroplasty, Pain, Postoperative, Adductor Canal Block
Interventions
Multimodal Peripheral Nerve Block Injection, Single Shot Adductor Canal Block, Initial Bolus, Continuous infusion
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 27, 2026, 1:19 PM EDT
Terminated No phase listed Observational

An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term

NCT04577144
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Online survey only
Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

NCT03248947
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone, Pharmacist-administered buprenorphine/naloxone maintenance care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 27, 2026, 1:19 PM EDT
Active, not recruiting Phase 3 Interventional

Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl

NCT06089707
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naloxone Nasal Spray
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine

NCT00679458
View directory record Official record
Conditions
Pain
Interventions
buprenorphine and low-dose naloxone, buprenorphine alone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-6000

NCT03002961
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, Suboxone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine Disposition and CYP3A

NCT01576575
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine Control, Buprenorphine + Rifampin, Buprenorphine + Grapefruit juice, Buprenorphine + Ketoconazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 27, 2026, 1:19 PM EDT
Active, not recruiting Not applicable Interventional

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

NCT05288751
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Contingency Management
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block

NCT03117140
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Ropivacaine 0.75%, Ropivacaine 0.75% + 300 mcg Buprenorphine, Ropivacaine 0.75% + 75 mcg clonidine, Ropivacaine 0.75% + 8 mg dexamethasone
Drug
Lead sponsor
Melinda Seering
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 27, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

NCT00880841
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine / Naloxone
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions

NCT00992095
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
buprenorphine hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 27, 2026, 1:19 PM EDT
Not yet recruiting Not applicable Interventional

Integrating MOUD in Nonmedical Community Settings (Better Together)

NCT06416020
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
HC-MOUD Only, BT-MOUD with Buprenorphine
Behavioral
Lead sponsor
Howard University
Other
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

NCT01157169
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 27, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 27, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

NCT00768482
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant), Sublingual Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers

NCT02477267
View directory record Official record
Conditions
Opiate Dependence
Interventions
SL spray, SL film
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Sep 27, 2026, 1:19 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

NCT05419297
View directory record Official record
Conditions
Back Pain Lower Back Chronic, Chronic Pain
Interventions
Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep
Drug · Other · Device + 1 more
Lead sponsor
Carolinas Pain Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 27, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional

Long-Term Treatment of Opioid Use Disorder

NCT05534815
View directory record Official record
Conditions
Drug Addiction, Employment
Interventions
Employment-based abstinence reinforcement
Behavioral
Lead sponsor
Northern Michigan University
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Marquette, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 27, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

NCT02310581
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine Sublingual Spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 27, 2026, 1:19 PM EDT